The global biomarker market size was estimated to be USD 67.39 billion in 2023 and is expected to reach at USD 275.07 billion by 2034 with a CAGR of 13.64% during the forecast period 2024-2034. Growing prevalence of cancer, rising investments in biomarker for significant innovations, surge in research & development activities, increasing adoption of biomarkers in infectious disease diagnosis, growing approvals by regulatory bodies, rising launch of advanced platforms, surge in strategic initiatives such as mergers, acquisitions, partnerships, & collaborations by market players, growing significance of companion diagnostics, and increasing developments in biomarkers such as biomarker signatures are some of the key factors boosting the market growth.
Increasing developments in biomarkers such as biomarker signatures is predicted to boost the market growth during the forecast period. A biomarker, also known as a biological marker, is a quantifiable sign that reflects the biological state or health of an organ, tissue, or cell. Biomarkers have extensive applications in fields such as medicine, safety evaluation, and the exploration of new drugs. They hold significant significance in enhancing drug development procedures and the broader realm of biomedical research. Consequently, industry stakeholders are emphasizing the advancement of cutting-edge biomarkers for the purpose of drug discovery. For instance, in October 2023, Sengenics Corporation LLC, a leader in immune response profiling to support scientific discovery and diagnostic development, announced the launch of i-Ome Discovery, to advance immune biomarker discovery and development.
By type, safety was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the growing usage of safety biomarkers in drug discovery & development, surge in the number of people who are at high risk of contracting diseases including renal problems, cancer, & heart disorders, and rising growing awareness regarding routine health checkups. Additionally, efficacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities, and growing collaborations within academic institutes & companies. For instance, in April 2022, A Cooperative Research & Development Agreement has been signed between Annovis Bio, Inc. and the National Institute on Aging with the aim of creating biomarkers for Parkinson's disease. This effort is in conjunction with their product buntanetap, which is intended for the treatment of both Alzheimer's disease and Parkinson's disease.
By disease, cancer was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the surge in demand for rapid & accurate diagnostic tools, rising prevalence of cancer, and increasing demand for personalized medicines. Additionally, cardiovascular diseases is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of CVDs, increasing focus on the development of cardiac biomarkers, and surge in approvals by regulatory bodies. For instance, in March 2022, CardiNor AS has received CE marking for its CardiNor Secretoneurin ELISA test, which is designed for precise prediction of cardiovascular risk and effective patient care management.
By application, drug discovery & development was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the increasing research & development activities and growing adoption of biomarkers in drug discovery. Additionally, personalized medicine is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of personalized medicine in chronic diseases, growing awareness regarding personalized medicine among healthcare professionals, and increasing collaborations within market players. For instance, in February 2023, Roche has revealed an extension of its partnership with Janssen to strengthen personalized healthcare solutions through companion diagnostics. This agreement broadens their efforts to encompass a diverse range of companion diagnostics, including biomarkers obtained from tissue and blood, digital pathology, and sequencing.
By end-user, hospitals & specialty clinics was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the surge in prevalence of chronic diseases, increasing focus on development of innovative biomarkers, and growing approvals by regulatory bodies. For instance, in March 2023, Abbott has obtained FDA clearance to make the first commercially available traumatic brain injury (TBI) blood test accessible to hospitals across the United States. This test, conducted using the Alinity i laboratory instrument, analyzes blood biomarkers and provides clinicians with a rapid and impartial method for assessing individuals with mild TBIs or concussions. Additionally, diagnostics & research laboratories is predicted to grow at fastest CAGR during the forecast period owing to the rising investment for the development of novel biomarkers by market players, growing technological advancements in the development of biomarker-based diagnostics, and increasing funding from public & private organizations for drug discovery and development.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of various diseases, rising awareness regarding biomarkers, increasing technological advancements, surge in healthcare infrastructure, and growing technological advancements. For instance, in November 2022, Akoya Biosciences, Inc. has introduced PhenoCode signature panels designed for the discovery of spatial biomarkers in a high-throughput manner. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing funding for biomarkers discovery, surge in prevalence of cancer, growing research & development activities, and rising partnerships within market players. For instance, in January 2023, Thermo Fisher Scientific has formed a strategic alliance with AstraZeneca to create companion diagnostic tests for Tagrisso, which can be used with both blood-based and solid tissue samples. These tests have the ability to detect multiple biomarkers in a single assay and enable swift and precise identification of patients who can benefit from targeted therapy.
Increasing developments in biomarkers such as biomarker signatures is predicted to boost the market growth during the forecast period. A biomarker, also known as a biological marker, is a quantifiable sign that reflects the biological state or health of an organ, tissue, or cell. Biomarkers have extensive applications in fields such as medicine, safety evaluation, and the exploration of new drugs. They hold significant significance in enhancing drug development procedures and the broader realm of biomedical research. Consequently, industry stakeholders are emphasizing the advancement of cutting-edge biomarkers for the purpose of drug discovery. For instance, in October 2023, Sengenics Corporation LLC, a leader in immune response profiling to support scientific discovery and diagnostic development, announced the launch of i-Ome Discovery, to advance immune biomarker discovery and development.
By type, safety was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the growing usage of safety biomarkers in drug discovery & development, surge in the number of people who are at high risk of contracting diseases including renal problems, cancer, & heart disorders, and rising growing awareness regarding routine health checkups. Additionally, efficacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities, and growing collaborations within academic institutes & companies. For instance, in April 2022, A Cooperative Research & Development Agreement has been signed between Annovis Bio, Inc. and the National Institute on Aging with the aim of creating biomarkers for Parkinson's disease. This effort is in conjunction with their product buntanetap, which is intended for the treatment of both Alzheimer's disease and Parkinson's disease.
By disease, cancer was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the surge in demand for rapid & accurate diagnostic tools, rising prevalence of cancer, and increasing demand for personalized medicines. Additionally, cardiovascular diseases is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of CVDs, increasing focus on the development of cardiac biomarkers, and surge in approvals by regulatory bodies. For instance, in March 2022, CardiNor AS has received CE marking for its CardiNor Secretoneurin ELISA test, which is designed for precise prediction of cardiovascular risk and effective patient care management.
By application, drug discovery & development was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the increasing research & development activities and growing adoption of biomarkers in drug discovery. Additionally, personalized medicine is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of personalized medicine in chronic diseases, growing awareness regarding personalized medicine among healthcare professionals, and increasing collaborations within market players. For instance, in February 2023, Roche has revealed an extension of its partnership with Janssen to strengthen personalized healthcare solutions through companion diagnostics. This agreement broadens their efforts to encompass a diverse range of companion diagnostics, including biomarkers obtained from tissue and blood, digital pathology, and sequencing.
By end-user, hospitals & specialty clinics was the highest revenue-grossing segment in the global biomarker market in 2023 owing to the surge in prevalence of chronic diseases, increasing focus on development of innovative biomarkers, and growing approvals by regulatory bodies. For instance, in March 2023, Abbott has obtained FDA clearance to make the first commercially available traumatic brain injury (TBI) blood test accessible to hospitals across the United States. This test, conducted using the Alinity i laboratory instrument, analyzes blood biomarkers and provides clinicians with a rapid and impartial method for assessing individuals with mild TBIs or concussions. Additionally, diagnostics & research laboratories is predicted to grow at fastest CAGR during the forecast period owing to the rising investment for the development of novel biomarkers by market players, growing technological advancements in the development of biomarker-based diagnostics, and increasing funding from public & private organizations for drug discovery and development.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of various diseases, rising awareness regarding biomarkers, increasing technological advancements, surge in healthcare infrastructure, and growing technological advancements. For instance, in November 2022, Akoya Biosciences, Inc. has introduced PhenoCode signature panels designed for the discovery of spatial biomarkers in a high-throughput manner. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing funding for biomarkers discovery, surge in prevalence of cancer, growing research & development activities, and rising partnerships within market players. For instance, in January 2023, Thermo Fisher Scientific has formed a strategic alliance with AstraZeneca to create companion diagnostic tests for Tagrisso, which can be used with both blood-based and solid tissue samples. These tests have the ability to detect multiple biomarkers in a single assay and enable swift and precise identification of patients who can benefit from targeted therapy.
Segmentation: Biomarker Market Report 2023 - 2034
Biomarker Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Efficacy
- Safety
- Validation
Biomarker Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Immunological Diseases
- Cardiovascular Diseases
- Cancer
- Neurological Diseases
- Others
Biomarker Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery & Development
- Diagnostics
- Personalized Medicine
- Others
Biomarker Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Hospitals & Specialty Clinics
- Diagnostics & Research Laboratories
- Others
Biomarker Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biomarker Market: Type Estimates & Trend Analysis
8. Biomarker Market: Disease Estimates & Trend Analysis
9. Biomarker Market: Application Estimates & Trend Analysis
10. Biomarker Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Biomarker Market
13. Europe Global Biomarker Market
14. Asia Pacific Global Biomarker Market
15. Latin America Global Biomarker Market
16. MEA Global Biomarker Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Abbott
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories Inc.
- QIAGEN
- Sengenics Corporation LLC
- Annovis Bio Inc. Epigenomics AG
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
- General Electric
